Predictors of fatigue after treatment for prostate cancer

Maliski, Sally L.; Kwan, Lorna; Orecklin, James R.; Saigal, Christopher S.; Litwin, Mark S.

doi:10.1016/j.urology.2004.08.031

Cited by 26 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Monga et al, 12 in a study meeting this requirement, found the rate of severe fatigue to be 40% among RAD patients with no initial ADT, at a mean time of 16.2 months after initiation of RAD, however, without identification of current hormone users. Our observations add to the results of these studies of fatigue in prostate cancer survivors, [9][10][11][12][13] showing that fatigue is a problem after local treatment even in patients without ADT.…”

Section: Discussionsupporting

confidence: 74%

“…Younger age at diagnosis, high neuroticism, presence of pain, post-treatment co-morbidity and urinary and intestinal dysfunction were significantly associated with CF in the multivariate analysis, with the highest numerical point estimate for high neuroticism. Fatigue or loss of vitality, to a certain degree reflecting fatigue, has been reported in several surveys of prostate cancer survivors, [9][10][11][12][13] often assessed as a dimension of a generic QoL instrument such as the RAND 36-Item Health Survey (SF-36) or the EORTC QLQ C30. However, in most studies patients who never received ADT cannot be separated from those with previous or ongoing hormone treatment.…”

Section: Discussionmentioning

confidence: 99%

“…7,8 The prevalence of fatigue as a late adverse effect after treatment for localized prostate cancer is 15-40% after RAD 9-13 and 10-17% after RP. 9,10,13 However, there are differences in the definition of fatigue, followup time and heterogeneity of samples explaining the variation in prevalence figures. In particular, fatigue has rarely been studied in hormone-naïve prostate cancer survivors after RP and RAD, and no study has examined CF in such samples.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy

Kyrdalen

Dahl

Hernes

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored associations between CF and medical and psychosocial variables. A population-based, cross-sectional postal survey in 2006 included Norwegian hormone-naïve survivors with the diagnosis of prostate cancer in 2004 who were treated with RP (n ¼ 337) or RAD (n ¼ 184). The primary outcome variable was prevalence of CF (defined as fatigue lasting 6 months or longer). Twelve to 32 months after RP and RAD, 13.4 and 26.1% of the patients after, respectively, RP and RAD reported CF inversely associated with pretreatment age (P ¼ 0.003). In multivariate analysis, high neuroticism, post-treatment co-morbidity, pain, urinary and intestinal dysfunction, but not sexual dysfunction, were positively associated with reporting CF. Further studies of CF in prostate cancer survivors should take into consideration the survivors' pretreatment medical and psychosocial situation.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy

Kyrdalen

Dahl

Hernes

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…10 Furthermore, numerous studies reported association of ADT with fatigue, decrease in bone mass, higher percentage of body fat, decrease in lean muscle mass, and increased incidence of fractures. 10,[13][14][15] Recent studies described an increase in cardiovascular morbidity and mortality, but this association remains controversial. [16][17][18] Several previous studies have reported on the effects of ADT on physical well-being.…”

mentioning

confidence: 99%

“…9 Similarly, health-related quality of life outcomes have been shown to be severely impacted by ADT. 14,[19][20][21][22] However, most studies evaluating effects of ADT on physical well-being have been limited to a small number of participants, have lacked pretreatment information, or have followed patients only to the immediate post-treatment period.…”

mentioning

confidence: 99%

Impact of androgen deprivation on physical well‐being in patients with prostate cancer

Sadetsky

Greene

Cooperberg

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: As androgen deprivation therapy (ADT) becomes a standard of treatment for men with recurrent or metastatic prostate cancer, evaluation of adverse effects associated with this treatment is needed. In this study, the authors evaluated the effect of ADT administered as monotherapy and in combination with local treatment on physical well-being in a longitudinal sample of men with prostate cancer. METHODS: Exposure to ADT was defined by 3 groups: local (local treatment only), combination (local treatment with adjuvant and/or neoadjuvant ADT), and primary ADT. Associations between exposure to ADT and physical well-being measured by self-reported health-related quality of life outcomes over time were evaluated by repeated measures analysis using mixed modeling. Estimates adjusted for various clinical and demographic variables are reported. RESULTS: A total of 2922 men, who completed both pretreatment and follow-up health-related quality of life assessment, were identified from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. During 24 months of follow-up, exposure to ADT was associated with worse physical well-being compared with local treatment at all time points (P < .001). Being exposed to ADT as primary therapy was associated with more severe declines compared with combination therapy. CONCLUSIONS: The potential consequence of decline in physical well-being in patients exposed to ADT has to be included in treatment decision making. Cancer 2011;117:4406-

show abstract

Composite polymer electrolytes based on the low crosslinked copolymer of linear and hyperbranched polyurethanes

Hong

Shi

2007

J of Applied Polymer Sci

View full text Add to dashboard Cite

Low crosslinked copolymer of linear and hyperbranched polyurethane (CHPU) was prepared, and the ionic conductivities and thermal properties of the composite polymer electrolytes composed of CHPU and LiClO 4 were investigated. The FTIR and Raman spectra analysis indicated that the polyurethane copolymer could dissolve more lithium salt than the corresponding polymer electrolytes of the non crosslinked hyperbranched polyurethane, and showed higher conductivities. At salt concentration EO/Li ¼ 4, the electrolyte CHPU30-LiClO 4 reached its maximum conductivity, 1.51 Â 10 À5 S cm À1 at 258C. DSC measurement was also used for the analysis of the thermal properties of polymer electrolytes.

show abstract

Predictors of fatigue after treatment for prostate cancer

Cited by 26 publications

References 33 publications

Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy

Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy

Impact of androgen deprivation on physical well‐being in patients with prostate cancer

Composite polymer electrolytes based on the low crosslinked copolymer of linear and hyperbranched polyurethanes

Contact Info

Product

Resources

About